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Oral Presentations 9collection phases. These patterns were similar between transplant
teams caring for adult or pediatric donors and recipients. Among
responding centers, it appears that medical management of recipi-
ents and their related donors by the same provider is common, and
may not be viewed as a potential conflict-of-interest. Whether this
potential conflict-of-interest affects donor care is unclear, and
deserves further investigation.
Survey Responses *
Medical Informed Medical
Clearance Consent ManagementProvider responsible for donor care
Internist/Family Practitioner 1 (1) 0 (.) 2 (2)
Pediatrician 5 (6) 1 (1) 3 (3)
Heme/Onc Physician 5 (6) 2 (2) 2 (2)
Transplant Physician 71 (82) 72 (83) 78 (90)
Mid-level Provider 3 (3) 7 (8) 2 (2)
Nurse 0 (.) 3 (3) 0 (.)
Missing 2 (2) 2 (2) 2 (2)Role of donor provider in
care of Recipient
Simultaneous responsibility
for recipient’s care25 (29) 31 (36) 35 (40)May be involved in recipient’s care 38 (44) 35 (40) 32 (37)
Not involved in recipient’s care 16 (18) 17 (20) 14 (16)
Not involved in transplant
program or recipient’s care6 (7) 2 (2) 4 (5)Missing 2 (2) 2 (2) 2 (2)*No. Responding Centers (%).17
BK VIRUS INFECTION IS ASSOCIATED WITH HEMATURIA AND RENAL
IMPAIRMENT IN RECIPIENTS OF ALLOGENEIC HEMATOPOETIC STEM
CELL TRANSPLANTS
O’Donnell, P.H.1, Swanson, K.1, Josephson,M.A.2, Artz, A.S.1, Rich, E.1,
Stock,W.1, van Besien, K.1 1The University of Chicago, Chicago, IL; 2The
University of Chicago, Chicago, IL
BK virus (BKV) is an important pathogen and cause of nephrop-
athy in recipients of renal transplants, but its clinical significance in
patients (pts) following hematopoetic stem cell transplantation
(HSCT) is less well described. Over a 16 month period we prospec-
tively measured BKV in the blood and urine of 124 pts who had
undergone allogeneic HSCT [HLA-identical donor (n 5 70), alter-
native-donor (HLA-mismatched-related, matched-unrelated, or
cord) (n 5 54)] between 1998–2007 and who were receiving
in- or outpatient post-transplant care. Most pts (73%) received
alemtuzumab-containing regimens. BK viruria was manifest at
some time in 64.8% of pts; 16.9% developed BK viremia. All pts
with BK viremia also had viruria. BK viruria developed at a median
time post-HSCT of 24 d (range 3–138 d), while viremia was de-
tected at a significantly longer median time of 128 d (range 62–
307 d) (P\0.0001). Among clinical factors (disease, transplant
type, alemtuzumab use, CMV viremia, GVHD, HLA C locus sta-
tus), only CMV viremia was significantly more common in pts with
BK viruria and viremia. Given the association of BKV with hemor-
rhagic cystitis, urinalyses from all pts were analyzed for the pres-
ence and number of red blood cells. There was a direct
relationship between higher median and maximum levels of urinary
BKV with both an increased occurrence, and greater degree, of mi-
croscopic hematuria (P\0.03). BK viremia was also associated with
the development of hematuria (P 5 0.03). Finally, BKV infection
was analyzed along with other clinical factors in relation to the de-
velopment of post-HSCT renal impairment. On multivariate anal-
ysis, only BK viremia (P 5 0.000001) and undergoing an
alternative-donor transplant (P 5 0.002) were independent predic-
tors of development of post-HSCT renal impairment, with BK
viremia associated with a median 1.62 mg/dL rise in creatinine
from the pre-transplant baseline. Two pts with BK viremia
developed biopsy-proven BKV nephropathy, with both requiring
hemodialysis. In summary, BK viruria is a common early findingin pts undergoing allogeneic HSCT, and higher urinary BKV levels
are directly related to increased hematuria. BK viremia occurs later
and less commonly, is associated with hematuria, and is an inde-
pendent predictor of worsening renal function post-HSCT. Inves-
tigation of whether prophylaxis against, or treatment of, BKV in the
post-HSCT setting mitigates the associated morbidities, especially
kidney injury, warrants prospective evaluation.18
HHV6 REACTIVATION IS AN IMPORTANT RISKFACTOR FOR POOR
OUTCOMES IN MYELOABLATIVE, BUT NOT IN NON-MYELOABLATIVE
TREATED ALLOGENEIC HSCT PATIENTS
Pagter, A.P.J.1, Meijer, E.4, Keukens, L.1, Schutten, M.5,
Cornelissen, J.J.4, Baarle, D.3, Fries, E.2, Schuurman, R.2,
Boelens, J.J.1 1University Medical Center, Utrecht, Netherlands; 2Uni-
versity Medical Center, Utrecht, Netherlands; 3University Medical Cen-
ter, Utrecht, Netherlands; 4Erasmus Medical Center, Rotterdam,
Netherlands; 5Erasmus Medical Center, Rotterdam, Netherlands
Background: Haematopoietic stem cell transplantation (HSCT)
is complicated by viral reactivations. Viral reactivations are major
complications after HSCT. The role of Human Herpesvirus type
6 (HHV6) in complications after HSCT remains unclear. We found
a strong association between HHV6 reactivation and poor outcome
after HSCT in children after myeloablative conditioning regimens.
Risk factors for the development of HHV6 reactivation in adults
are unknown.We investigated the association of HHV6 reactivation
and clinical outcomes.
Methods: In a retrospective cohort study (January 2005- Decem-
ber 2007), HHV6DNA loads in plasma were monitored by realtime
PCR in adult patients after allogeneic HSCT in two HSCT-centers
in the Netherlands (Utrecht and Rotterdam). Previously, Epstein
Barr virus (EBV)- and cytomegalovirus (CMV) DNA loads were
prospectively monitored in these patients. EBV- and CMV-reactiva-
tions were pre-emptive treated according to local guidelines. HHV6
reactivation was defined as viral DNA load $1000 cp/mL. Associa-
tions between outcomes and various variables (age, gender, HSCT
center, donor source, HLA match of donor and recipient, myeloa-
blative (MA) versus non-myeloablative (NMA) conditioning regi-
men, EBV- and CMV-reactivation) were analyzed using Cox
proportional hazard models.
Results: 108 patients (60 MA and 48 NMA recipients; 49
Utrecht and 59 Rotterdam) between 2005 and 2007 were in-
cluded (median age 40.1; range 18- 66 years). Median follow-
up was 20 (range 1.4–35.8) months. 16/60 (27%) MA patients
had HHV6 reactivation (mean 50323 cp/mL) compared to 2/
48 (4%) NMA patients with marginal HHV6 reactivation
(mean 1000 cp/mL). Median time of reactivation for HHV6 in
MA patients was 19 (range 10–35) days, compared to 14 and
35 days in the 2 NMA patients. In multivariate analysis, MA con-
ditioning was the only predictor for HHV6 reactivation (HR
0.15; 95%CI 0.03–0.65; p 5 0.012). In addition, HHV6 reactiva-
tion was the only predictor for grade $2 acute Graft versus
host disease (HR 6,2, 95%CI 2,8- 13,9; p 5 0.000) and
Transplantation related mortality (HR 3,9, 95% CI 1.4–10.7;
p 5 0.010).
Conclusions: Early HHV6 reactivation is more common after
MA than after NMA conditioning treatment and is associated with
poor survival and severe acute GvHD. Screening for HHV6 reacti-
vation might be important in the MA treated patients since early ini-
tiation of pre-emptive or prophylactic anti-viral treatment might
influence the outcomes.19
NATURAL KILLER (NK) CELLS ARE RESISTANT TO THE APOPTOTIC EF-
FECTS OF CORTICOSTEROIDS COMPARED TO T CELLS: IMPLICATIONS
FOR ADOPTIVE NK CELL THERAPY FOLLOWING ALLOGENEIC HCT
Ramanathan, M., Lundqvist, A., Yokoyama, H., Smith, A., Childs, R.
National Institute of Health, Bethesda, MD
In vivo animal data and preliminary data in humans show donor
NK cells can mediate antitumor effects against malignancies when
adoptively infused following allogeneic hematopoietic cell
10 Oral Presentationstransplantation (HCT). Therapeutic administration of corticoste-
roids is often required after HCT to treat acute and chronic graft
versus host disease (GVHD). Although corticosteroids are known
to induce T-cell apoptosis and suppress T-cell cytotoxic function,
their effects on NK cells have not been well characterized. We in-
vestigated for differences between T cells and ex vivo expanded NK
cells in their susceptibility to apoptosis and inhibition of prolifera-
tion following treatment with corticosteroids. T and NK cells were
isolated by magnetic bead separation from peripheral blood mono-
nuclear cells. NK cells were expanded in X-vivo 20 with 10%
human AB serum, 500U/ml IL-2 and irradiated (100Gy) Epstein-
Barr virus transformed B cells for 7 days. T cells were expanded
for 5 days in RPMI 1640 supplemented with IL-2. Hydrocortisone
was used in vitro at concentrations (0.5ug/mL to 20ug/mL) compa-
rable to drug levels achieved in patients receiving 1mg/kg to 1 gram
of methylprednisolone . Apoptosis, cellular proliferation and the
cytolytic function of T and NK cells against K562 cells were eval-
uated by flow cytometry staining for annexin-V and 7-AAD, thymi-
dine incorporation and 51Cr-release assays respectively. Compared
to T-cells, NK cells were resistant to the apoptotic and anti-prolif-
erative effects of hydrocortisone; hydrocortisone concentrations of
0.5ug/ml and 20ug/mL inhibited T-cell proliferation by 60% (p5
0.005) and 80% (p 5 0.001) respectively, whereas steroids at these
same doses did not inhibit NK cell proliferation (table). In contrast
to T-cells, NK cells were resistant to steroid-induced apoptosis; at
steroid concentration of 20ug/mL 81% of T cells (grown in serum
free media) stained positive for annexin-V versus 42% of NK cells
(table). NK cell cytolytic function against K562 targets was not af-
fected by steroid exposure; at an NK cell: K562 ratio of 1:1, NK
cells treated with 0, 0.5ug/ml, and 20ug/ml of hydrocortisone lysed
35%, 33%, and 27% of K562 targets respectively (p 5 n.s.). These
findings show that NK cells are resistant to the immunosuppressive
effects of corticosteroids compared to T-cells and further suggest
that corticosteroid administration following allogeneic HCT may
not preclude a beneficial anti-tumor effect of adoptively infused
donor NK cells.
Steroid Effect on Apoptosis and Proliferation of Tand NK cells
Steroid %T cell % NK cell T NK
Concentration Apoptosis Apoptosis P cell SI* cell SI* P0 ug/mL 73% 45% 1 1
0.5 ug/mL 77% 40% 0.009 0.4 1.07 0.004
20 ug/mL 81% 42% 0.02 0.16 0.98 0.005
200 ug/mL 95% 38% 0.06 0.01 0.69 0.05SI*. Stimulation Index.20
IN SITU ACTIVATION OF HOST CD41 CD251 FOXP31 T CELLS: A NEW
STRATEGYFORCIRCUMVENTINGRESISTANCEANDESTABLISHMENTOFHE-
MATOPOIETIC ENGRAFTMENT AFTER MHC-MATCHED ALLOGENEIC HCT
Shatry, A., Levy, R.B. University of Miami Miller School of Medicine,
Miami, FL
Treg infusions have been shown to suppress HVG and GVH in
experimental allogeneic HCT. These findings have engendered
enthusiasm for the administration of Tregs in the clinical setting.
We hypothesized that activation/expansion of Tregs in situ may
represent an approach that obviates the requirement to isolate
and enrich Treg populations for use in such transplants. To ad-
dress this question, we administered a complex of IL-2 and
anti-IL2 mAb (IAC) to recipients following reduced intensity
conditioning (RIC) and allogeneic MHC-matched HCT. A pro-
tocol was identified which significantly enhanced early donor chi-
merism, and importantly, facilitated long-term multi-lineage
engraftment in these recipients. Administration of this complex
relative to the time of HCT was crucial: post-HCT treatment
with IAC more efficiently facilitated marrow engraftment com-
pared to pre-HCT administration. Donor chimerism remained
present .27 weeks post-HCT. One week post-HCT, the fre-
quency of host Tregs as well as CD25 expression (MFI) were sig-
nificantly elevated in IAC-treated vs. control recipients. Toaddress a potential mechanism for these observations, we assessed
host-anti-donor (tetramer1) CD8 T cells that arise post-HCT
and mediate resistance to engraftment. IAC but not control
(PBS) treatment suppressed the emergence of these host tet-
ramer1 expressing CD8 T cells early post-HCT. Following in
vivo administration of donor antigen into chimeric and non-
chimeric recipients .6 months post-HCT, an increased
frequency of tetramer1 CD8 cells was observed only in non-
chimeric marrow allograft recipients. Importantly, LPS and
anti-CD3 responses by splenocytes from both groups of recipi-
ents were comparable. Hence, we conclude that the inhibition
of host anti-donor reactive CD8 cells was not associated with
global immune suppression in chimeric animals and may indicate
tolerance in these recipients. In total, these findings are consis-
tent with the notion that the transient activation/expansion of
host Tregs in situ post-HCT can be explored as a new strategy
to regulate host alloreactivity post-transplant. Notably, the in
situ stimulation of recipient Tregs following RIC obviated the in-
fusion of Tregs and may represent an alternative approach to,
and/or complement – the adaptive transfer of Treg populations
in clinical HCT.21
PRE-TRANSPLANT RISK ASSESSMENT IN ADULT ACUTE LYMPHOCYTIC
LEUKEMIA
Terwey, T.H.1, Massenkeil, G.2, le Coutre, P.1, Hemmati, P.1,
Neuburger, S.1, Dorken, B.1, Arnold, R.1 1Charite, Campus
Virchow-Klinikum, Berlin, Germany; 2Gu¨tersloh General Hospital, Gu¨-
tersloh, Germany
Introduction: Hematopoietic cell transplantation (HCT) can
be curative in hematological malignancies but the procedure is
associated with significant risks. Several scoring systems have
been developed to predict transplant-related mortality (TRM)
and overall survival (OS), however none has become a standard
in clinical decision making yet. In the present study we compared
the prognostic value of the HCT Comorbidity Index (HCT-CI)
(Sorror ML, Blood 2005), the Pretransplantation Assessment of
Mortality score (PAM) (Parimon T, Ann Intern Med 2006), the
EBMT risk score (ERS) (Gratwohl A, Lancet 1998) and the Kar-
nofky-Index (KI) in 151 adult patients who received HCT for
acute lymphocytic leukemia (ALL) from 1995 until 2007 at our
center.
Methods: Risk scores were calculated as defined in the original
publications based on data extracted from patient charts, dis-
charge letters and computer databases. Median age was 31 years
(16–67). Disease status was first complete remission (CR) (n 5
72), higher CR (n 5 31) and no CR (n 5 48). Patients received
high-dose (HD) (n 5 138) or reduced intensity conditioning
(RIC) (n 5 13) and bone marrow (n 5 41) or peripheral blood
stem cells (n 5 110) from related (n 5 63) or unrelated (n 5 88)
donors. Graft-versus-host-disease (GVHD) prophylaxis was
CSA/MTX for HD or CSA/MMF for RIC. OS was assessed by
Kaplan-Meier curves and logrank statistics, cumulative incidence
of relapse mortality and NRM was assessed by competitive risk
analysis.
Results:Median follow-up was 48 months (5–144). OS at 1, 3
and 5 years was 62% (55–69), 45% (37–54) and 40% (31–49).
Deaths were due to relapse (n 5 47), GVHD (n 5 15), infections
(n 5 17) or other causes (n 5 8). According to HCT-CI criteria
comorbid conditions were present in 98 patients with liver dis-
ease (n 5 43), lung disease (n 5 34) and infections (n5 34) being
the most common. Median scores for HCT-CI, PAM, ERS and
KI were 1 (0–10), 24 (15–36), 3 (0–6) and 90% (60–100), respec-
tively. We found that the HCT-CI and PAM were not predictive
for OS or NRM whereas the EBMT risk score and KI were able
to predict outcome based on differences in relapse mortality
(Table 1).
Conclusions: 65% of ALL patients undergoing HCT at our cen-
ter had significant pre-transplant comorbidities as assessed byHCT-
CI criteria. ERS and KI had discriminative potential for OS and re-
lapse incidence, however prediction of NRM was not possible with
the examined indices. Further research is needed to optimize risk
assessment in ALL patients.
